Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial
March 1, 2024
Phase 2 study showing that SABR for RCC is safe and feasible for those who refuse or are not candidates for surgery. The median age was 77, and this seems to be a safe, noninvasive alternative.
